Description
Mpd-1 is an investigational medication currently being studied in clinical trials for advanced solid tumors, including colorectal cancer. It is being evaluated in a Phase 1 trial to determine its safety, how well it is tolerated, and how the body processes the drug (pharmacokinetics). This early-phase trial helps researchers find the right dose for further studies. The trial is open-label, meaning both the researchers and participants know who is receiving the drug. The trial is being conducted at a single center. Mpd-1 is being studied in patients with advanced solid tumors, and the specific trial mentioned (NCT06944457) is recruiting participants. The trial includes patients with KRAS or PTEN mutations, which are common genetic changes found in some colorectal cancers.
Mechanism of Action
The specific way Mpd-1 works (its mechanism of action) is still under investigation. It is an investigational drug, and researchers are working to understand its effects on cancer cells and the body.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.